Pharma & Biotech Global Week in Review 23 Sept 09 from IP Think Tank

Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

 
Highlights this week included:

CAFC upholds patentability of drug dosage method claim: Prometheus v Mayo (Patently-O) (Patent Baristas) (Patents4Life) (Holman’s Biotech IP Blog) (Patent Docs) (Inventive Step) (Patently-O)

Mircera (Recombinant erythropoietin) – US: CAFC: Section 121 ‘safe harbor’ provision does not apply to continuations: Amgen v Hoffman-La Roche (Peter Zura’s 271 Patent Blog) (Patent Baristas) (Holman’s Biotech IP Blog)

 
General

Patent expiry = job cuts: discussion of Marketwatch article on Eli Lilly job cuts (Innovationpartners)

China: IPR protection for traditional Chinese medicine needed (IP Dragon)

EU sets out H1N1 flu strategy; partners with Pharma on medicines development (Intellectual Property Watch)

India: Patent oppositions in India: The ‘efficacy’ of section 3(d) (Spicy IP)

India/EU: PhRMA speaks out against seizure of drug consignments (Spicy IP)

Rwanda: 18 September marks last shipment of low-cost HIV/AIDS medicines under WTO sanctioned arrangement (Intellectual Property Watch)

US: CAFC upholds patentability of drug dosage method claim: Prometheus v Mayo (Patently-O) (Patent Baristas) (Patents4Life) (Holman’s Biotech IP Blog) (Patent Docs) (Inventive Step) (Patently-O)

US: Roll Call authors unite against current follow-on biologics legislation (Patent Docs)

US: Will KSR’s effect on small molecule patents be limited? (Intellectual Property Watch)

 
Products

Coversyl (Perindopril) – Australia: FCA decision a reminder to review issued patent claims in view of newly emerged prior art before filing suit: Apotex Pty Ltd v Les Laboratoires Servier (Patent Baristas)

Duac (Clindamycin, Benzoyl) – Perrigo acquires KV Pharmaceutical’s first to file ANDA for generic Duac gel (GenericsWeb)

Mircera (Recombinant erythropoietin) – US: CAFC: Section 121 ‘safe harbor’ provision does not apply to continuations: Amgen v Hoffman-La Roche (Peter Zura’s 271 Patent Blog) (Patent Baristas) (Holman’s Biotech IP Blog)

Oracea (Doxycycline) – US: Impax confirms challenge relating to Galderma’s Oracea patents (SmartBrief)

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: